High mobility group box-1 protein--one step closer to the clinic?
- PMID: 18671827
- PMCID: PMC2575561
- DOI: 10.1186/cc6944
High mobility group box-1 protein--one step closer to the clinic?
Abstract
High mobility group box (HMGB)1, originally described as a nuclear protein that binds to and modifies DNA, is now regarded as a central mediator of inflammation by acting as a cytokine. HMGB1 is postulated to be particularly important as a late acting mediator of lethal septicaemia in mice. Furthermore, it has been suggested that HMGB1 plays a role in clinical conditions such as autoimmunity, acute ischaemia-reperfusion injury, cardiovascular disease and cancer. HMGB1 has emerged as a candidate for therapeutic intervention in various disease conditions. However, further basic and clinical studies are warranted to confirm the roles played by HMGB1 in clinical medicine.
Comment on
-
Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome.Crit Care. 2008;12(3):R83. doi: 10.1186/cc6935. Epub 2008 Jun 24. Crit Care. 2008. PMID: 18577209 Free PMC article.
References
-
- Wang HC, Bloom O, Zhang MH, Vishnubhakat JM, Ombrellino M, Che JT, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–251. doi: 10.1126/science.285.5425.248. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
